Mir Ali Hashim

US Patent:

20030096839, May 22, 2003

Filed:

Jun 13, 2002

Appl. No.:

10/149722

Inventors:

Alison Floyd - Durham NC, US
Mir Hashim - Durham NC, US
Robert Mook - Durham NC, US
Andrea Sefler - Durham NC, US
Kathleen Meserve - Durham NC, US
Patricia Ricciarelli - Durham NC, US
Timothy Spitzer - Durham NC, US

International Classification:

A61K031/47
A61K038/38

US Classification:

514/307000, 514/002000

Abstract:

The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipient for use in the formulations of invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.

US Patent:

20100272827, Oct 28, 2010

Filed:

Jul 7, 2009

Appl. No.:

12/459862

Inventors:

Mir Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Sanjay Patel - Palo Alto CA, US
Ronald J. Berenson - Mercer Island WA, US

International Classification:

A61K 33/42
A61K 33/26
A61P 7/06

US Classification:

424604, 424646

Abstract:

Embodiments provide devices, systems and methods for the transdermal delivery of chelated compounds. One embodiment provides a method for the iontophoretic transdermal delivery of a chelated iron complex for the treatment of anemia. A first patch comprising an active electrode and a chelated iron complex is applied to the skin; a second patch containing an electrode is also applied. An electrical current is then delivered to the skin from the active electrode. The chelated complex is transported across the skin via electromotive force from the current, with the iron being substantially chromogenically unreactive with the skin during transport so that there is little or no tattooing of the skin due to the formation of insoluble oxidative products. The complex is then dissociated by phagocytosis or related process to release the iron where it may be bound by transferrin or ferritin and carried to other sites for storage or metabolic use.

US Patent:

20110208270, Aug 25, 2011

Filed:

Aug 3, 2010

Appl. No.:

12/849574

Inventors:

Mir A. Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Emily Arnsdorf - San Carlos CA, US

Assignee:

InCube Labs, LLC - San Jose CA

International Classification:

A61N 1/36

US Classification:

607 62

Abstract:

Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.

US Patent:

20120177700, Jul 12, 2012

Filed:

Dec 27, 2011

Appl. No.:

13/338210

Inventors:

Mir A. Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Lu Wang - San Jose CA, US
Sanjay Patel - Palo Alto CA, US
Joel M. Harris - Mountain View CA, US
Phil Morgan - San Antonio TX, US

International Classification:

A61K 9/00
A61K 33/42
B82Y 5/00

US Classification:

424400, 424604, 977773, 977915

Abstract:

Embodiments of the invention provide nanonized iron compositions for treatment of iron deficiency such as iron deficiency anemia. Many embodiments provide nanonized iron compositions which are sized to minimize adverse reaction such as immune response, adverse GI reaction and allergic reaction to iron compound included in the composition. The nanonized iron compositions can be used in a variety of drug delivery forms, including an oral dosage form, a transdermal patch, in an intravenous solution or in a dialysate for treatment of a patient with chronic kidney disease (CKD). Embodiments of the invention also provide methods of using the nanonized iron compositions for the treatment of iron deficiency in a patient in need thereof including patients with iron deficiency anemia and CKD.

US Patent:

20120184894, Jul 19, 2012

Filed:

Jan 3, 2012

Appl. No.:

13/342948

Inventors:

Mir Imran - Los Altos Hills CA, US
Phil Morgan - San Antonio TX, US
Mir Hashim - Fremont CA, US
Joel Harris - Mountain View CA, US

International Classification:

A61N 1/30

US Classification:

604 20

Abstract:

Embodiments of the invention provide patches for the transdermal delivery of compositions to treat an individual suffering from hair loss. Many embodiments provide an iontophoretic patch for the transdermal delivery hair growth stimulating agents for the treatment of hair loss by stimulating the growth of new hair in areas of the scalp exhibiting hair loss. The patch comprises an electrode and a reservoir containing a composition comprising iron containing compound, such as a chelated iron compound for the delivery of the therapeutically effective amount of iron. The patch can be shaped to be placed and remain on the head. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a hair growth stimulating agent such as a chelated iron compound, minoxidil and finasteride to the scalp and other areas exhibiting hair loss. Such methods can be used for re-growing hair, and/or preventing or slowing hair loss.

US Patent:

20130023815, Jan 24, 2013

Filed:

Mar 26, 2012

Appl. No.:

13/430662

Inventors:

Mir Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Glen McLaughlin - San Carlos CA, US
Huma Arastu - San Jose CA, US
Rekha Vaidyanathan - San Jose CA, US
Joel Harris - Mountain View CA, US
Radhika Korupolu - San Jose CA, US
Andrew Mangogna - San Jose CA, US
Chang Ong - San Jose CA, US
Sanjay Patel - San Jose CA, US
Lu Wang - San Jose CA, US
Timothy Williams - San Jose CA, US

International Classification:

A61N 1/30

US Classification:

604 20, 604501

Abstract:

Various embodiments provide methods and systems for the biphasic iontophoretic transdermal delivery of therapeutic agents. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient. Embodiments may be used for delivery of agents which cause adverse effects from unwanted passive diffusion.

US Patent:

20130023850, Jan 24, 2013

Filed:

May 7, 2012

Appl. No.:

13/466116

Inventors:

Mir Imran - Los Altos Hills CA, US
Talat Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US

International Classification:

A61N 1/30

US Classification:

604501

Abstract:

Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., nicotine compounds for the treatment of nicotine cravings from tobacco use. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient.

US Patent:

20140039378, Feb 6, 2014

Filed:

Sep 11, 2013

Appl. No.:

14/024539

Inventors:

Talat Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US

Assignee:

InCube Labs, LLC - San Jose CA

International Classification:

A61N 1/30

US Classification:

604 20

Abstract:

Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., from nicotine. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into skin. A dose of agent is delivered from the assembly into skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel agent out of the assembly. During a second period, a second current having a characteristic to attract agent is used to retain agent in the assembly such that delivery of agent into skin is minimized. In particular embodiments, a dose of agent may be delivered on-demand using an input from the patient using an inhalation sensing device which mimics an inhaled form of tobacco.